Pulmonology

Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.

Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.

Real-world data from CHEST 2026 show ETI improved lung function and BMI in children with CF aged 6 to 11, with the most gains in F508del homozygotes.

New non-CF bronchiectasis in Medicare is tied to high health care use and $8998 PPPM FFS spending; prevalence is highest in older women.

Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.

HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.

Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.

Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk stratification.

Jorgen Vestbo, MD, on the COPERNICOS trial results, long-term antibiotic use versus resistance concerns, and where COPD treatment is headed.

Yet Khor discusses why a 20% CT emphysema threshold, not spirometry alone, best identifies CPFE and predicts outcomes in fibrotic ILD.

John R. Hurst, MD, PhD, explains how BEAM-302 gene editing targets both lung and liver disease in alpha-1 antitrypsin deficiency.

Francesca Puggioni, MD, explains how multidisciplinary teams choose COPD biologics and why systemic inflammation matters as much as FEV1.

A Chest study of 1576 patients finds a 20% emphysema threshold best predicts survival and lung function decline in fibrotic ILD.

Mass spectrometry technology identified proteomic biomarkers of IPF, but more work will be needed to fully translate these findings to the clinic.

The approval was based on the pivotal phase 3 FIBRONEER-ILD trial, in which nerandomilast slowed lung function decline in PPF and had similar discontinuation rates to placebo.

The 2025 American Thoracic Society International Conference brought advancements in pulmonary medicine and highlighted the need for health equity reforms.

Patients with pulmonary fibrosis (PF) obtain much of their information from the internet, a new report finds, even though a significant amount of information on the internet is incomplete or inaccurate.

Nerandomilast slowed disease progression at 2 doses compared with placebo among US participants in the trial.

A national analysis of CDC data over 25 years revealed persistent sex, racial, and regional disparities in pneumonia and pulmonary fibrosis mortality.

The FDA has expanded sotatercept's indications for pulmonary arterial hypertension, following data showing significant drops in hospitalization and mortality risks.

Atomic force microscopy successfully identified nanomechanical changes in fibrotic lung tissue.

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment.

A wearable cough monitor generated clinically useful cough data, but patients only wore the device about half of the days of the study period.

Patients with progressive pulmonary fibrosis had longer survival with antifibrotic therapy, but only if they met a key criteria.

Patients with acute exacerbations of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis face steep odds and benefit from palliative care.